22:11 , May 9, 2019 |  BC Extra  |  Company News

Management tracks: Akebia, Sangamo, Bicycle

Kidney disease company Akebia Therapeutics Inc. (NASDAQ:AKBA) said SVP and CMO Rita Jain will step down, effective June 17, to pursue other opportunities. She will be succeeded by Steven Burke, who was SVP and CMO...
17:44 , Mar 15, 2019 |  BC Week In Review  |  Clinical News

Mitsubishi Tanabe planning Japanese submission for vadadustat

Akebia said partner Mitsubishi Tanabe plans to submit a regulatory application in Japan this year for vadadustat to treat anemia due to chronic kidney disease (CKD) after reporting that the product met the primary endpoints...
00:47 , Feb 16, 2019 |  BC Extra  |  Company News

Management tracks: Nimbus, Ascentage, Cadent, Skyhawk

Computational biology company Nimbus Therapeutics LLC (Cambridge, Mass.) hired Peter Tummino as CSO. He was VP and global head of lead discovery at the Janssen Pharmaceuticals Inc. unit of Johnson & Johnson (NYSE:JNJ). Nimbus’ previous...
00:50 , Jan 5, 2019 |  BC Extra  |  Company News

Flurry of management moves on eve of JPM

More than 30 biopharma companies announced executive changes to kick off the New Year, including Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) and Immunocore Ltd. (Abingdon, U.K.), both of which brought on former AstraZeneca plc (LSE:AZN; NYSE:AZN) executives...
23:44 , Nov 19, 2018 |  BC Extra  |  Company News

Management tracks: Brickell, Genevant

Dermatology company Brickell Biotech Inc. (Boulder, Colo.) hired Robert Brown as CEO, effective Jan. 1. He will replace co-founder and CEO Reginald Hardy, who will remain on the board and serve as special adviser to...
22:21 , Aug 30, 2018 |  BC Extra  |  Company News

Management tracks: Lilly, Kiadis

Eli Lilly and Co. (NYSE:LLY) said SVP and President of Lilly Oncology Sue Mahony will retire, effective Aug. 31. She is succeeded by Anne White, who is VP of portfolio management and Lilly's Chorus R&D...
18:06 , Jun 29, 2018 |  BC Week In Review  |  Company News

Renal plays Akebia, Keryx merging

Akebia Therapeutics Inc. (NASDAQ:AKBA) will merge with Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) in an all-stock deal, forming a combined company with one chronic kidney disease compound on the market and another in Phase III testing. Keryx...
22:09 , Jun 28, 2018 |  BC Extra  |  Company News

Renal plays Akebia, Keryx merging

Akebia Therapeutics Inc. (NASDAQ:AKBA) will merge with Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) in an all-stock deal, forming a combined company with one chronic kidney disease compound on the market and another in Phase III testing. The...
17:58 , Mar 30, 2018 |  BC Week In Review  |  Financial News

Akebia raises $89.3M in follow-on

Kidney disease company Akebia Therapeutics Inc. (NASDAQ:AKBA) raised $89.3 million on March 23 through the sale of 8.5 million shares at $10.50 in a follow-on underwritten by Morgan Stanley. The price is a 10% discount...
16:24 , Mar 23, 2018 |  BC Extra  |  Financial News

Akebia raises $89.3M in follow-on

Akebia Therapeutics Inc. (NASDAQ:AKBA) raised $89.3 million through the sale of 8.5 million shares at $10.50 in a follow-on underwritten by Morgan Stanley. The price is a 10% discount to Akebia's close of $11.68 on...